SelK 2

Drug Profile

SelK 2

Alternative Names: Anti P-selectin glycoprotein ligand-1; Anti-PSGL-1-mAb - Tetherex; SelK-2

Latest Information Update: 11 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Selexys Pharmaceuticals
  • Developer Tetherex Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action P-selectin ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Crohn's disease
  • Discontinued Multiple myeloma

Most Recent Events

  • 11 Jun 2018 Discontinued - Preclinical for Multiple myeloma in USA (Parenteral)
  • 01 Jun 2018 Phase-I clinical trials in Crohn's disease in USA (Parenteral) before June 2018 (Tetherex website, June 2018)
  • 18 Apr 2018 Tetherex Pharmaceuticals plans two phase II trials for Venous thromboembolism and Crohn's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top